Free tool
Rare disease stocks
We cover 51 companies grouped under the Rare disease theme. The median market value in the group is $2.60B. Across the group, the median move over the past trading day is −0.28%. 67% of the 49 with a 200-day average trade above it. Price change over the past year runs from −75.2% to +207.1% across the middle 80 percent of the group, with a median of +46.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
51 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.19 | +0.05% | +11.54% | +15.03% | Oct 26, 2026 |
| PTGX | Protagonist Therapeutics, Inc. | $151.50 | +10.71% | +73.78% | +146.62% | Nov 5, 2026 |
| IMVT | Immunovant, Inc. | $43.89 | +12.83% | +69.39% | +189.13% | Nov 9, 2026 |
| CRNX | Crinetics Pharmaceuticals, Inc. | $84.84 | +1.17% | +81.55% | +179.08% | Nov 5, 2026 |
| 4151.T | Kyowa Kirin Co., Ltd. | 2,613.00 JPY | −3.33% | +3.94% | +4.01% | Nov 2, 2026 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $111.87 | +3.54% | +6.53% | +9.35% | Nov 3, 2026 |
| SRRK | Scholar Rock Holding Corporation | $60.04 | +21.61% | +40.28% | +74.18% | Nov 12, 2026 |
| ORKA | Oruka Therapeutics, Inc. | $99.44 | +9.94% | +251.75% | +555.07% | Nov 11, 2026 |
| LQDA | Liquidia Corporation | $71.36 | −17.81% | +127.26% | +154.86% | Nov 3, 2026 |
| TVTX | Travere Therapeutics, Inc. | $67.12 | +20.05% | +69.84% | +284.86% | Oct 29, 2026 |
| DNTH | Dianthus Therapeutics, Inc. | $110.76 | +9.01% | +179.13% | +356.93% | Nov 5, 2026 |
| PTCT | PTC Therapeutics, Inc. Common Stock | $72.69 | −3.58% | −5.28% | +46.02% | Nov 5, 2026 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $78.68 | −0.96% | +87.31% | +133.47% | Oct 27, 2026 |
| MIRM | Mirum Pharmaceuticals, Inc. | $98.51 | −12.22% | +26.18% | +31.96% | Nov 4, 2026 |
| DYN | Dyne Therapeutics, Inc. | $26.36 | +1.78% | +42.49% | +93.26% | Nov 5, 2026 |
| EWTX | Edgewise Therapeutics, Inc. | $44.38 | +9.99% | +86.86% | +207.13% | Nov 5, 2026 |
| MANE | Veradermics, Incorporated | $102.80 | −7.84% | +172.32% | +172.32% | Nov 12, 2026 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $37.08 | +89.67% | +224.69% | +292.38% | Nov 5, 2026 |
| CAMX.ST | Camurus AB (publ) | 615.00 SEK | −1.68% | +0.49% | −15.35% | Nov 5, 2026 |
| CLDX | Celldex Therapeutics, Inc. | $40.57 | +14.02% | +50.20% | +79.51% | Nov 9, 2026 |
| IRON | Disc Medicine, Inc. | $82.67 | +10.74% | +4.53% | +37.90% | Nov 5, 2026 |
| ARQT | Arcutis Biotherapeutics, Inc. | $25.14 | −11.54% | −13.31% | +60.64% | Oct 27, 2026 |
| VRDN | Viridian Therapeutics, Inc. | $24.26 | +24.35% | −20.93% | +30.71% | Nov 5, 2026 |
| VERA | Vera Therapeutics, Inc. | $36.82 | +10.50% | −24.27% | +67.21% | Nov 5, 2026 |
| RARE | Ultragenyx Pharmaceutical Inc. | $26.44 | +1.77% | +12.03% | −12.10% | Nov 3, 2026 |
| PHVS | Pharvaris N.V. | $37.00 | +9.97% | +39.73% | +55.59% | Nov 12, 2026 |
| TRVI | Trevi Therapeutics, Inc. | $17.92 | −2.77% | +50.71% | +124.00% | Nov 12, 2026 |
| NKTR | Nektar Therapeutics | $73.77 | +4.24% | +69.90% | +151.95% | Nov 12, 2026 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $9.83 | +0.92% | +31.07% | +15.38% | Nov 2, 2026 |
| COAG | Hemab Therapeutics Holdings, Inc. | $49.19 | +4.08% | +44.68% | +44.68% | Nov 16, 2026 |
| MLYS | Mineralys Therapeutics, Inc. | $25.89 | −3.93% | −27.50% | +70.22% | Nov 10, 2026 |
| PVLA | Palvella Therapeutics, Inc. | $154.33 | +8.04% | +53.90% | +173.39% | Nov 11, 2026 |
| AUPH | Aurinia Pharmaceuticals Inc. | $16.54 | +10.56% | +7.75% | +36.58% | Nov 9, 2026 |
| ADMA | ADMA Biologics, Inc. | $9.63 | +9.56% | −46.14% | −44.17% | Nov 4, 2026 |
| ZBIO | Zenas BioPharma, Inc. | $33.04 | +2.32% | −4.23% | +97.73% | Nov 12, 2026 |
| STOK | Stoke Therapeutics, Inc. | $33.09 | +12.59% | +7.09% | +71.45% | Nov 3, 2026 |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $33.99 | −5.56% | +25.06% | −13.45% | Oct 29, 2026 |
| GOSS | Gossamer Bio, Inc. | $0.17 | −15.17% | −93.96% | −92.93% | Nov 4, 2026 |
| SPRO | Spero Therapeutics, Inc. | $1.22 | +2.09% | −48.09% | −38.38% | Nov 12, 2026 |
| SCYX | SCYNEXIS, Inc. | $5.67 | +56.20% | +787.32% | +579.04% | Nov 4, 2026 |
| ATYR | aTyr Pharma, Inc. | $0.55 | +11.54% | −27.40% | −89.34% | Nov 5, 2026 |
| MCRB | Seres Therapeutics, Inc. | $4.76 | −0.83% | −68.58% | −74.79% | Nov 4, 2026 |
| MREO | Mereo BioPharma Group plc | $0.28 | −10.03% | −45.49% | −84.20% | Nov 9, 2026 |
| QNCX | Quince Therapeutics, Inc. | $31.31 | +61.64% | +4.37% | +100.71% | Nov 12, 2026 |
| RVX.TO | Resverlogix Corp. | 0.10 CAD | 0.00% | 0.00% | 0.00% | Nov 12, 2026 |
| JSPR | Jasper Therapeutics, Inc. | $0.72 | +13.43% | −60.98% | −75.24% | Nov 10, 2026 |
| TVRD | Tvardi Therapeutics, Inc. | $1.78 | −27.05% | −56.37% | −94.18% | Nov 12, 2026 |
| INM | InMed Pharmaceuticals Inc. | $1.43 | −14.37% | +27.68% | −36.44% | Sep 23, 2026 |
| JAGX | Jaguar Health, Inc. | $0.92 | −4.63% | −97.37% | −98.52% | Nov 12, 2026 |
| XRTX | XORTX Therapeutics Inc. | $2.22 | +8.20% | −22.18% | −43.99% | Nov 12, 2026 |
| APLI.TO | Appili Therapeutics Inc. | 0.02 CAD | +50.00% | −40.00% | −25.00% | Nov 12, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.